The pharmacological inhibitors of ERK, p38, and JNK all antagonized visfatin-mediated activities, suggesting that visfatin promotes AP-1-dependent MMP-2 production and chondrosarcoma migration through ERK, p38, and JNK signaling. Here, MMP2 is linked to chondrosarcoma.